Further investigation revealed that the expression, phosphorylation, and activity of MAPK1, MAPK3, and CDK1 had increased; thus, these three kinases could serve as potential drug targets for GC patients (Fig. 1f). This evidence concerns the gene CDK1 and gastric cancer.